When Chris Cargill became president and CEO of Sosei Heptares in March 2022, high on his initial to-do list were a number of items around the transition of the Japan-UK company to the next stage of its journey.
There were four main strategic goals: make the company’s R&D unit as effective as possible; put translational medicine at the...



![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)


